NCT06111443
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
StatusActive, Not Recruiting
PhasePhase 2/3
SponsorChang Gung Memorial Hospital
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Freedom from all atrial tachyarrhythmias (AF/AFL/AT)
Timeframe: 3,6 and 12 months after ablation
Secondary (12)
Freedom from all atrial tachyarrhythmias (AF/AFL/AT) excluding the 3-month blanking period
Freedom from all atrial tachyarrhythmias (AF/AFL/AT) within 3-month blanking period
Total mortality or hospitalization due to CV cause
Left atrial (LA) size (LA dimension and LA volume index) by echocardiography
AF quality of life (QOL) by AF Effect On Quality-Of-Life (AFEQT) questionnaire score
Show 7 moreShow less
N-terminal pro-brain natriuretic peptide (NT-proBNP) level
Glycated Hemoglobin (HBA1c)
Creatinine (Cr) and estimated Glomerular filtration rate (eGFR)
Urine albumin/Cr ratio level
Repeated catheter ablation or cardioversion for atrial tachyarrhythmia
Adverse events: hypoglycemia, hypotension, hypokalemia, renal function deterioration
AF burden
Arms and interventions
DapagliflozinExperimental
Dapagliflozin (FORXIGA) 10 mg QD for 3 months
Usual careNo intervention
guideline-direct usual care
Drugs: Dapagliflozin 10 mg [Farxiga]
Sites
1 site in 1 country
- Kaoshiung Chang Gung MemorialKaohsiung City, Taiwan